ES8701230A1 - Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores - Google Patents

Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores

Info

Publication number
ES8701230A1
ES8701230A1 ES549115A ES549115A ES8701230A1 ES 8701230 A1 ES8701230 A1 ES 8701230A1 ES 549115 A ES549115 A ES 549115A ES 549115 A ES549115 A ES 549115A ES 8701230 A1 ES8701230 A1 ES 8701230A1
Authority
ES
Spain
Prior art keywords
viii
inhibitor
preparation
treatment
cag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES549115A
Other languages
English (en)
Other versions
ES549115A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordisk Gentofte AS
Original Assignee
Nordisk Gentofte AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordisk Gentofte AS filed Critical Nordisk Gentofte AS
Publication of ES549115A0 publication Critical patent/ES549115A0/es
Publication of ES8701230A1 publication Critical patent/ES8701230A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO DE PRODUCCION DE PREPARACIONES PARA EL TRATAMIENTO DE PACIENTES DE HEMOFILIA A INHIBIDORES, QUE CONTIENEN UNA PROTEINA O PEPTIDO CON ACTIVIDAD DE FACTOR VIII:CAG ESPECIFICA DE AL MENOS 0,5 U/MG DE PROTEINA, SIENDO LA RELACION ENTRE LA ACTIVIDAD DE FACTOR VIII:CAG Y LA ACTIVIDAD PROCOAGULANTE DE FACTOR VIII:C SUPERIOR A 5:1 Y PREFERIBLEMENTE A 10:1. CONSISTE EN TRATAR UNA SOLUCION QUE CONTIENE FACTOR VIII:CAG CON UN INMUNOABSORBENTE QUE CONTIENE ANTICUERPOS ESPECIFICOS AL FECTOR VIII:CAG LIGADO A PARTICULAS SOLIDAS Y LUEGO DISOLVER EL VIII:CAG LIGADO POR ELUCION CON UNA SOLUCION TAMPON, Y ELABORARLO EN UNA PREPARACION POR SECADO, DIALISIS, FILTRACION DE GEL O INTERCAMBIO IONICO.
ES549115A 1984-11-05 1985-11-05 Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores Expired ES8701230A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK525384A DK525384D0 (da) 1984-11-05 1984-11-05 Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat

Publications (2)

Publication Number Publication Date
ES549115A0 ES549115A0 (es) 1986-12-01
ES8701230A1 true ES8701230A1 (es) 1986-12-01

Family

ID=8140859

Family Applications (1)

Application Number Title Priority Date Filing Date
ES549115A Expired ES8701230A1 (es) 1984-11-05 1985-11-05 Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores

Country Status (11)

Country Link
US (1) US4831119A (es)
EP (1) EP0201574B1 (es)
JP (1) JPH0713026B2 (es)
AT (1) ATE69727T1 (es)
AU (1) AU599310B2 (es)
CA (1) CA1269042A (es)
DE (1) DE3584775D1 (es)
DK (1) DK525384D0 (es)
ES (1) ES8701230A1 (es)
IL (1) IL76929A (es)
WO (1) WO1986002838A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
AU5952090A (en) * 1989-06-15 1991-01-08 William I. Smith Jr. Method and apparatus for inactivating infectious agents in and resisting coagulation of biological fluids
DE69034042T2 (de) * 1989-08-02 2003-07-17 Mitra Medical Technology Ab Lu System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
DK162233C (da) * 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IT1256622B (it) * 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
IL156842A0 (en) * 2001-02-05 2004-02-08 Novo Nordisk Healthcare Ag Combined use of factor vii polypeptides and factor ix polypeptides
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
ES2558102T3 (es) * 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2006003183A1 (de) * 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448945B (sv) * 1979-12-20 1987-03-30 Blombaeck E G B Forfarande for rening och /eller koncentrering av faktor viii-komplexet
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
AU555305B2 (en) * 1982-09-29 1986-09-18 Bayer Corporation Antihemophilic factor concentrate
US4406886A (en) * 1983-01-14 1983-09-27 University Patents, Inc. Purification of antihemophilia factor VIII by precipitation with zinc ions
WO1984003628A1 (en) * 1983-05-09 1984-09-27 Nordisk Insulinlab A concentrate of the antihemophilic factor viii and a process for producing it
US4649132A (en) * 1983-03-31 1987-03-10 Scripps Clinic And Research Foundation Treatment of Factor VIII inhibitors
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
FI852866L (fi) * 1984-07-27 1986-01-28 Meloy Lab Rekombinantfaktor viii-r.

Also Published As

Publication number Publication date
ES549115A0 (es) 1986-12-01
IL76929A0 (en) 1986-04-29
EP0201574B1 (en) 1991-11-27
JPS62501006A (ja) 1987-04-23
DK525384D0 (da) 1984-11-05
JPH0713026B2 (ja) 1995-02-15
AU5092685A (en) 1986-06-03
DE3584775D1 (de) 1992-01-09
CA1269042A (en) 1990-05-15
US4831119A (en) 1989-05-16
WO1986002838A1 (en) 1986-05-22
ATE69727T1 (de) 1991-12-15
AU599310B2 (en) 1990-07-19
EP0201574A1 (en) 1986-11-20
IL76929A (en) 1990-07-26

Similar Documents

Publication Publication Date Title
ES8701230A1 (es) Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores
US4877614A (en) Biologically active fragments of human antihemophilic factor and method for preparation thereof
RU95115239A (ru) Аналог эритропоэтина
EP1175909A8 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
CA2032153A1 (fr) Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
EP1308515A3 (en) Porcine factor VIII
DE68916932T2 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
CA2248960A1 (en) Stable factor viii/vwf-complex
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
IL84700A (en) Hybrid proteins,dnas coding therefor,hybrid vectors containing such dnas and hosts transformed therewith,the preparation of such hybrid proteins and pharmaceutical compositions containing them
Stathakis et al. Human fibrinogen heterogeneities. Preparation and characterization of γ and γ′ chains
HUT50195A (en) New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
AU3595489A (en) Amblyommin, a new active substance for anticoagulant therapy
Ferguson et al. Localization of the disulfide bond in human antithrombin III required for heparin-accelerated thrombin inactivation
DOOLITTLE et al. Synthetic peptide probes and the location of fibrin polymerization sites
NO991653L (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
Araujo et al. Potentiation of bradykinin action on smooth muscle by a scorpion venom extract
Montgomery et al. The carbohydrate-protein linkage in ovomucoid
DK318086A (da) Praeparat til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadant praeparat
EP0675135A2 (en) Protein PHBP-70, having heparin binding and fibroblast proliferating properties
Iwanaga et al. Amino acid sequence and biological activity of a histidine-rich peptide released from high molecular weight bovine kininogen by plasma kallikrein